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The gaseous free radical nitric oxide is an important
biologic mediator with physiologic and pathophysiologic
roles in nearly every organ system. Because of its unique
biologic activity, unusual chemical structure, and unpre-
cedented mechanisms of action, nitric oxide, arguably
more than any other natural product, has opened new
avenues to investigate cellular processes. Nitric oxide is
generated in biologic tissues by specific nitric oxide
synthases that metabolize arginine and molecular oxygen
to citrulline and nitric oxide. Besides its function as a
diffusible messenger in the vasculature and in neurons,
nitric oxide also plays a key role in innate immunity and
inflammation. Recent progress has allowed the identi-
fication of the nitric oxide pathway in several cell types
that reside in the skin, including keratinocytes, melano-
Known for decades as an atmospheric pollutant, nitricoxide (NO) is also produced by cells in several tissuesof the body. Although potentially harmful when inhaled,it is essential for many biologic functions (Nathan,1992). To date, NO has been observed in over a dozen
cell types in various parts of the body. Cells in the central and peripheral
nervous system, the lung, the liver, the gastrointestinal tract, the blood
vessels, the immune system, and also the skin are known to generate
the molecule (Knowles and Moncada, 1994). In some instances, NO
acts as a messenger molecule in cell-to-cell communication (Lowenstein
and Snyder, 1992). It is through this mode of action that NO mediates
vasodilation, neurotransmission, penile erection, intestinal peristalsis,
and probably other autonomic functions as well (Moncada and Higgs,
1993; Biliar, 1995). But NO is also a potent cellular toxin, either
protecting the body against invading pathogens and tumor cells or
destroying normal cells and tissues (Liew and Cox, 1991). The latter
mode of action is of central importance for the role of NO in host
immune defense, immunoregulation, and autoimmune tissue injury
(Kolb and Kolb-Bachofen, 1992; Ånggård, 1994).
Recent work on the biology of the skin has extended our understand-
ing of the complex cellular responses mediated by this highly pervasive
signaling molecule. Thus, NO can be made by several cell types that
reside in the skin, and increasing data indicate that this simple inorganic
gas serves as an autocrine and paracrine mediator in diverse and
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cytes, Langerhans cells, fibroblasts, and endothelial cells.
Convincing evidence suggests that nitric oxide synthesis
in these cells can be modulated by calcium-mobilizing
agonists as well as diverse inflammatory and immune
stimuli, and thereby contributes to the pathogenesis of
several human skin diseases. Characterization of these
intrinsic and extrinsic regulatory stimuli of nitric oxide
synthesis has afforded substantial insights into the role of
nitric oxide in inflammatory, hyperproliferative, and
autoimmune skin diseases, as well as skin cancer, and
may ultimately form the basis for future therapeutic
intervention. The demonstrable and potential roles of
nitric oxide in skin disease pathogenesis and treatment
are the subjects of this review. Key words: cellular
signaling/immune regulation/skin biology. J Invest Dermatol
110:1–7, 1998
complex cellular processes throughout the skin (Heck et al, 1992;
Kolb-Bachofen et al, 1994; Becherel et al, 1995). Not only is NO
normally involved in maintaining skin homeostasis, it can also directly
modify several skin reactions. Regulation of vasodilation, melano-
genesis, and protective responses to invading pathogens are well-
studied examples of this biologic activity of NO in human skin
(Goldsmith et al, 1996; Weller et al, 1996; Romero-Graillet et al, 1997).
The ability to affect these processes is partially attributed to its unusual
chemical properties (Knowles and Moncada, 1994). Thus, its reactions
with molecular oxygen, metal chelates, and metalloproteins activate or
inactivate target enzymes of various metabolic pathways and dominate
the chemistry of NO (Butler et al, 1995). Conversely, disruption of
the NO signaling cascade has been shown to be associated with
many clinically important conditions and diseases. These range from
inflammatory, hyperproliferative, and autoimmune skin diseases to skin
cancer (Xie et al, 1995; Villiotou and Deliconstantinos, 1995; Becherel
et al, 1996; Bruch-Gerharz et al, 1996). Elucidation of the role of NO
in these diseases may lead to a better understanding of their pathogenesis
and may provide opportunities for the development of new mechanism-
based therapies.
BIOSYNTHESIS OF NO
A major effort in understanding the dichotomous functions of NO has
centered on identifying the different enzyme isoforms of NO synthases.
Figure 1 schematically illustrates the reaction catalyzed by NO synthase;
additional characteristics are depicted in Table I. In the presence of
molecular oxygen and catalyzed by the enzyme NO synthase, the
guanidino nitrogen of arginine undergoes a five-electron oxidation
to yield the gaseous free radical, NO, and citrulline in equimolar
concentrations. Flavin mononucleotide, flavin adenine dinucleotide,
protoporphyrin IX heme, and tetrahydrobiopterin (BH4) are essential
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Figure 1. Biosynthesis of NO. NO is generated by a class of NADPH-
dependent NO synthases, which catalyze the conversion of arginine to
citrulline and NO with a 1:1 stoichiometry. Three different isoenzymes have
been characterized: two of them are constitutive and calcium-/calmodulin-
activated (ecNOS and ncNOS), and one is an inducible, calcium-independent
isoform (iNOS).
Table I. Comparison of the constitutive and inducible NO
synthase isoforms in cells of human skin
Feature ec/ncNOS iNOS
Cellular sources in the Keratinocytes Keratinocytes
skin Melanocytes Langerhans cells
Fibroblasts Fibroblasts
Endothelial cells Endothelial cells
Activating signals Calcium influx
Ultraviolet irradiation
Inducing signals Shear stressa Bacterial endotoxins
Ultraviolet irradiationa Cytokines (e.g., IL-8,
IFN-γ, TNF-α, IL-1β)
Neuropeptides
Molecular targets Soluble guanylyl Key enzymes of the
cyclase mitochondrial respiratory




Amounts released Small Large
Picomolar Nanomolar
concentrations concentrations
Proposed functions Vasodilation Host immune defense




cofactors for this reaction. The flavins apparently store and donate
electrons to the heme group, which then catalyzes the oxidation
process. Tetrahydrobiopterin appears to be important in maintaining
the enzyme in its active dimeric form (Griffith and Stuehr, 1995).
Three different isoforms of NO synthases have been identified that are
encoded by separate genes located on different chromosomes. Two
constitutive NO synthase isoforms are localized in neuronal cells
(ncNOS or NOS1) or endothelium (ecNOS or NOS3), where
increased levels of intracellular Ca21 activate the enzymes via calmodu-
lin. The resulting short repetitive pulses of NO synthesis mediate rapid
events such as vasorelaxation and neurotransmission (Nathan, 1992).
The third isoform is calcium-independent and inducible (iNOS or
NOS2). This enzyme is transcriptionally regulated and therefore
requires new mRNA and protein synthesis for its activity (Cho et al,
1992). Inducible NO synthase operates in many different cell types –
sometimes in parallel with one of the constitutive enzymes – is active
for long periods of time, and synthesizes large amounts of NO. Enzyme
expression is typically induced by inflammatory and immune stimuli
such as interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and
interleukin (IL)-1β (Nathan, 1994). When synthesized at high concen-
trations, NO has been shown to play a decisive role in inflammatory and
autoimmune tissue injury due to its cytotoxic and immunoregulatory
properties (Kro¨ncke et al, 1997). Thus, the magnitude and kinetics of
NO synthesis by a mammalian cell determine whether its actions are
regulatory or cytotoxic.
REGULATION AND EXPRESSION OF NO SYNTHASE
The cell-specific isoforms of the enzyme NO synthase profoundly vary
in their distribution, regulation, and function (Fo¨rstermann et al, 1994;
Griffith and Stuehr, 1995). The following section summarizes data
about the regulation and expression of the different NO synthases with
particular reference to human skin.
As described above, the constitutive isoforms of NO synthase
are calcium- and calmodulin-dependent and the active enzymes are
homodimers of two subunits with molecular masses of µ135 kDa
(ecNOS) or 150–160 kDa (ncNOS). Phosphorylation of these isoforms
by protein kinases, specifically protein kinase C, has been reported to
result in subcellular translocation and inactivation of the enzyme
(Fo¨rstermann et al, 1994). It is well known that the constitutive
isoforms are expressed in endothelial cells (ecNOS) and neuronal cells
(ncNOS) from which the enzymes have been cloned, but both isoforms
are also found in other mammalian cells (Knowles and Moncada,
1994), including various cell types resident to the skin (Table I). In
the past few years, expression of the neuronal isoform has been observed
in keratinocytes as well as melanocytes (Dippel et al, 1994; Baudouin
et al, 1996; Romero-Graillet et al, 1996) and expression of the
endothelial isoform has been found in fibroblasts and endothelial cells
(Bull et al, 1996; Wang et al, 1996). Based on current knowledge, the
constitutive enzymes expressed in these cells are normally involved in
maintaining skin homeostasis and are thought to provide regulatory
functions as well. This is perhaps best exemplified by, but not restricted
to, the regulation of cutaneous blood flow as well as integration of
vasodilator responses to local warming, ultraviolet irradiation, or
injection of calcitonin gene-related peptide (Deliconstantinos et al,
1995; Goldsmith et al, 1996).
In contrast to the neuronal and endothelial NO synthase enzymes
that are always present but only active when intracellular calcium levels
increase, the inducible isoform is not expressed in resident cells but
can be induced in several cells after challenge with proinflammatory
cytokines and/or bacterial endotoxins (Nathan, 1992; Kro¨ncke et al,
1995). The inducible isoform exists in the active form as a homodimer
of two subunits with a molecular mass of 130 kDa. Of note,
the transcriptionally regulated induction of iNOS is inhibited by
glucocorticosteroids, cyclophilins, and retinoids and is decreased by
TGF-β, IL-4, and IL-10 (Becherel et al, 1995; Pinsky et al, 1995).
The inducible isoform was initially cloned from macrophages and
hepatocytes, but its presence has also been subsequently demonstrated
in endothelial cells, mesangial cells, chondrocytes, and many other
mammalian cell types (Xie and Nathan, 1994). In recent years,
continued progress has been made in the identification of the inducible
NO pathway in human skin, and it is now reasonable to propose that
this isoform can be expressed in all cell types of human skin (Table I).
Thus, keratinocytes express iNOS after cytokine challenge (Arany et al,
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Figure 2. Dual pathway mechanisms of NO. The formation of NO and
the subsequent regulatory and cytotoxic effects of NO in the intracellular and
extracellular milieu are listed.
1996; Bruch-Gerharz et al, 1996; Sirsjo et al, 1996) or after ligation of
CD23 (Fcε RII) (Becherel et al, 1996). Fibroblasts and dendritic cells
become iNOS positive after exposure to bacterial endotoxin plus IFN-
γ (Wang et al, 1996; Qureshi et al, 1996) and endothelial cells express
iNOS in addition to ecNOS after activation with IL-1β.1 The
regulation and function of the inducible isoform in cells of the skin
appears to be mainly associated with inflammatory and immune
responses and is implicated into the pathogenesis of a wide range of
human skin diseases2 (Heck et al, 1992; Xie et al, 1995; Bruch-Gerharz
et al, 1996; Wang et al, 1997).
To conclude, each NO synthase isoform exhibits distinct expression
patterns and unique mechanisms of regulation that partially account
for the different effects of NO, when synthesized in biologic cells and
tissues. As a consequence, the physiologic and pathophysiologic roles
of NO synthesis in human skin will depend considerably on the cellular
context, the type of NO synthase expression, and thus the properties
of NO that will be described in more detail below.
PROPERTIES OF NO
NO is a small gaseous radical that conveys biologic information in a
manner differing from all other classical mediators. NO does not bind
reversibly to specific membrane receptors, but forms covalent bonds
with molecular targets such as metal chelates and various metalloproteins
(Fig 2). In biologic systems, NO can reversibly react with proteins
containing reduced cystein moieties yielding S-nitrosothiols. These
unstable adducts spontaneously decompose, again liberating NO, and
thus may be regarded as a storage form of NO (Kro¨ncke et al, 1997).
By its covalent attachment to prosthetic iron groups or iron-sulfur
centers in proteins, NO can form complexes that activate or deactivate
target enzymes and thereby affect many types of cellular responses
(Stamler, 1994). It is through this mode of action that NO stimulates
one of its main target enzymes, the soluble guanylyl cyclase. Under
conditions of pulsatile low-output NO synthesis, activation of this
heme-containing enzyme increases intracellular cGMP concentrations,
resulting in vasorelaxation, neurotransmission, and mediation of auto-
nomic functions throughout the body (Schmidt and Walter, 1994).
Under conditions of continuous high-output NO synthesis, several
metabolic pathways can be inhibited by interactions between NO and
various metal-containing enzymes (Griffith and Stuehr, 1995). Thus,
the basis of NO-mediated cytotoxicity depends on the combination
of NO with metal-containing moieties in key enzymes of the mitochon-
drial respiratory chain leading to inhibition of mitochondrial electron
1Suschek C, Kro¨ncke KD, Kolb-Bachofen V: Inducible nitric oxide synthase
(iNOS) in human dermal endothelial cells. J Invest Dermatol 105:451, 1995
(abstr.).
2Kuhn A, Fehsel K, Lehmann P, Ruzicka T, Kolb-Bachofen V: Expression
of inducible nitric oxide synthase (iNOS) in human epidermis of lupus
erythematosus. J Invest Dermatol 107:504, 1996 (abstr.).
transport (Stamler, 1994), inhibition of aconitase activity affecting iron
metabolism (Weiss et al, 1995), and inhibition of ribonucleotide
reductase, the rate-limiting step in DNA synthesis (Kro¨ncke et al,
1997). Other experiments confirmed that NO can also damage DNA
directly by deamination of purine and pyrimidine bases resulting in
mutations and strand breaks (Nguyen et al, 1992). NO-mediated DNA
damage has been shown to induce p53 expression that arrests cell cycle
progression in G1 allowing for repair of damaged DNA (Meβmer et al,
1994). In addition, several recent experiments have demonstrated that
NO-induced DNA damage activates the nuclear poly (ADP-ribose)
polymerase accompanied by nicotinamide adenine dinucleotide and
adenosine-triphosphatase depletion leading to cell death by energy
deprivation (Heller et al, 1995). In this context, it is important to note
that NO-induced DNA damage triggers apoptosis as has been shown
for several immunocompetent cells, such as thymocytes, lymphocytes,
and macrophages (Fehsel et al, 1995). Moreover, NO causes autoribosyl-
ation of glyceraldehyde-3-phosphate dehydrogenase thereby blocking
glycolysis (Stamler, 1994).
A further cardinal mechanism of action is the alteration of gene
expression by inhibition of various nuclear transcription factors
(Kro¨ncke et al, 1996; Berendji et al, 1997). Thus, NO is able to induce
the release of zinc ions from zinc-sulfur cluster proteins via nitrosylation
and subsequent disulfide formation that results in the loss of DNA-
binding activity of zinc finger-type transcription factors as has been
demonstrated for AP-1, SP-2, and LAC9 (Tabuchi et al, 1994). Critical
involvement of NO formation has also been suggested to play a role
in redox regulation of transcription factors like NF-κB and has been
shown to induce and stabilize the NF-κB inhibitor IκB α (Shin
et al, 1996).
In recent years, it has become apparent that in addition to transition
metals, NO interacts with reactive oxygen intermediates to generate a
second line of reactive molecules that can attack an extended range of
nucleophilic targets. Thus, NO can react with superoxide to form
peroxynitrite, a potent inducer of lipid and protein peroxidation,
tyrosine nitration, and other free radical-mediated reactions (Kro¨ncke
et al, 1997). The biologic activities of NO and their modulation
therefore depend on the reactivities of both the gas and its reactive
products with many intracellular and extracellular targets.
Taken together, a growing body of evidence indicates that NO and
its reactive intermediates exert a number of diverse biologic effects by
reacting with transition metal- and thiol-containing proteins. These
chemical properties allow NO to serve as a multifunctional signaling
molecule as well as a potent cytostatic and cytotoxic effector molecule
active in inflammation, regulation of immune functions, and tumor
survival.
PHYSIOLOGIC AND PATHOPHYSIOLOGIC ROLES OF NO
Because NO bears this multitude of regulatory and effector functions
in normal homeostasis as well as in pathologic states, it has to be
expected that it plays a decisive role in clinically important conditions
and diseases. The following section provides a selective update of the
physiologic and pathophysiologic roles of NO as they relate to
cutaneous biology.
Vascular system Among the first places where NO was found to
have a biologic role was in the regulation of vascular homeostasis
(Ignarro, 1991; Moncada and Higgs, 1993). Endothelial cells produce
via ecNOS activity small pulses of NO resulting in a basal level of
vascular smooth muscle relaxation. In addition to the regulation of
systemic blood pressure, however, NO has recently been reported to
control the local blood flow to specific vascular beds, including the
brain, heart, lung, gastrointestinal tract, and skin (Nathan and Xie,
1994; Schmidt and Walter, 1994). A local deficiency of NO therefore
could cause vasospasm in selected organs. Through this mechanism
NO is thought to be involved in hepatorenal syndrome, in pre-
eclampsia, and also in Raynaud disease (Ånggård, 1994). Moreover, in
human skin the microvascular endothelial cells have been shown to
release NO in response to the vasodilatory neuropeptides calcitonin
gene-related peptide and substance P, suggesting that NO provides
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a molecular link between the nervous system and the skin (Bull
et al, 1996).
In addition to its role as an endothelium-derived vasodilator, NO
appears to be an endogenous inhibitor of vascular smooth muscle
cell growth and migration, NF-κB activity, and the expression of
proinflammatory molecules such as vascular cell adhesion molecule 1
(VCAM-1), endothelial leukocyte adhesion molecule-1 (ELAM-1 or
E-selectin), and, to a lesser extent, intercellular adhesion molecule-1
(ICAM-1) (Shin et al, 1996), thereby also regulating leukocyte traffick-
ing. Expression of iNOS in endothelial cells therefore could influence
the natural history of vascular diseases, including vasculitis and arterio-
sclerosis. In this context, it is interesting to note that iNOS expression
in vascular endothelial cells has been shown to mediate cytotoxicity
and basic fibroblast growth factor release in cultured vascular smooth
muscle cells, suggesting an important role of NO in the mechanism
of neovascularization of arteriosclerotic plaques (Fukuo et al, 1995).
Nervous system Abundant evidence indicates that NO synthesized
by ncNOS modulates neuronal activity in both the central and the
peripheral nervous system. In addition, NO plays a key role in nervous
system morphogenesis and synaptic plasticity, including long-term
potentiation as well as long-term depression, and is thus linked to the
formation of memory (Biliar, 1995). Besides its putative beneficial roles
as a neurotransmitter, however, long-term release of NO and NO
metabolites is exceedingly neurotoxic and contributes to tissue destruc-
tion following stroke, to neurodegenerative processes such as
Alzheimer’s disease, Huntington chorea, and AIDS dementia-complex,
and to experimentally induced neurologic diseases (Culotta and
Koshland, 1992; Bukrinsky et al, 1995). Moreover, inducible NO
synthase gene expression has been demonstrated in the vascular, glial,
and neuronal structures of the brain during systemic inflammation and
sepsis (Wong et al, 1996).
In its role as a neurotransmitter of the peripheral nervous system,
NO mediates several autonomic functions throughout the body, i.e.,
tonus regulation of smooth muscle cells in bronchi, stomach, and
intestine as well as in blood vessels (Schmidt and Walter, 1994).
Recently, the possible involvement of NO in the local regulation of
blood flow by perivascular nerves was discussed. In addition, possible
roles for NO in neurogenic inflammation as well as in several neurologic
disorders affecting the skin, such as neurotrophic ulcers as well as
diabetic microangiopathy and polyneuropathy, are also becoming
apparent (Burnstock and Ralevic, 1994).
Immune system Numerous studies have demonstrated that NO
synthesis is a necessary component of nonspecific defense mechanisms
for several pathogens, including bacteria, viruses, parasites, and fungi
(Liew and Cox, 1991). In particular, NO synthesized at high con-
centrations eliminates intracellular pathogens such as Mycobacterium
tuberculosis and Mycobacterium leprae, Leishmania species, Trypanosoma cruzi,
and Plasmodium falciparum, and is thought to block viral replication as
well (Kro¨ncke et al, 1995; Stenger et al, 1996). Initially, this type of NO-
mediated cytotoxicity was presumed to be restricted to macrophages;
however, it has now become apparent that other cell types that express
iNOS, such as hepatocytes, pulmonary epithelial cells, keratinocytes,
and endothelial cells, may also contribute to this innate immunity.
Specifically, the lung, the liver, the gastrointestinal tract, and the skin,
acting as immunologic barriers, appear to be well equipped for this
first line of defense.
It is currently well established that the scope of NO actions
touches the function of various immunocompetent cells. Produced by
macrophages, it enhances their phagocytic activity against bacteria as
well as neoplastic cells (Liew and Cox, 1991). Synthesized by endothelial
cells, NO acts as an endogenous modulator of lymphocyte adhesion
and leukocytic infiltration (Kro¨ncke et al, 1997). A key role for NO
has also been demonstrated in tumor-induced immunosuppression,
either directly by NO-producing tumor cells or indirectly via induction
of iNOS in tumor-infiltrating macrophages (Stuehr and Nathan, 1989).
On the other hand, production of NO in melanoma cells has been
associated with apoptosis, suppression of tumorigenicity, and abrogation
of metastasis (Xie et al, 1995).
Thus, evidence is accumulating that NO exerts important immuno-
regulatory effects preventing prolonged and deleterious activation of
the immune system. Moreover, several lines of evidence indicate that
inappropriate expression of iNOS plays a major role in many clinically
important inflammatory and autoimmune diseases. These range from
glomerulonephritis, ulcerative colitis, lupus erythematosus,2 and asth-
matic inflammation to rheumatoid arthritis as well as diabetes and
psoriasis (Kolb-Bachofen et al, 1992; Ånggård, 1994; Bruch-Gerharz
et al, 1996).
NO AND SKIN BIOLOGY: CURRENT STATUS
The skin is a site of significant immunologic activity because of its
constant exposure to environmental challenges such as physical stress,
trauma, chemical irritants, and infectious micro-organisms. In con-
sequence, a complex set of immune reactions can be observed in the
skin, providing an appropriate defense under a variety of circumstances.
The first indication that NO might be an integral part of the immune
response in human skin came from in vitro experiments showing that
inflammatory stimuli induce keratinocytes to produce NO as well as
hydrogen peroxide (Heck et al, 1992). These studies also demonstrated
that epidermal growth factor that promotes wound healing by stimulat-
ing cellular proliferation is a potent antagonist of NO synthesis by
epidermal keratinocytes. Based on these findings it has been suggested
that NO produced by keratinocytes is important in the control of
epidermal proliferation during wound healing.
In our own studies on the role of iNOS in psoriatic inflammation
we demonstrated iNOS expression in skin biopsies from patients with
psoriasis, but not in skin specimens from patients with atopic eczema
or from healthy volunteers (Kolb-Bachofen et al, 1994; Bruch-Gerharz
et al, 1996). In situ hybridization experiments eventually allowed us to
show that iNOS mRNA transcripts in epidermal keratinocytes of
psoriatic skin lesions were co-localized with mRNA transcripts of the
epidermal IL-8 receptor. This observation provided a mechanism to
link induction of iNOS with the characteristic neutrophil inflammation
in psoriasis. Indeed, our in vitro experiments demonstrated that especially
IL-8 plus γ-IFN but also TNF-α plus IL-1β are potent synergistic
inducers for iNOS expression in human keratinocytes.
A role for NO in allergic skin manifestations was also suggested,
because induction of iNOS in epidermal keratinocytes is achieved by
cross-linking the low-affinity receptors for IgE (CD23), expressed at
the surface of human epidermal keratinocytes (Becherel et al, 1996).
Correlative evidence exists that the therapeutic effects of retinoic acid
derivatives in common skin diseases are at least partially based on the
inhibition of the inducible NO pathway in human keratinocytes
(Becherel et al, 1995).
In addition, several lines of evidence indicate that NO is also involved
in the formation of sunburn erythema and edema (Deliconstantinos et al,
1995; Goldsmith et al, 1996). Thus, it has been demonstrated in
keratinocytes and endothelial cells that the constitutive neuronal NO
synthase pathway in keratinocytes can be activated for prolonged
periods of time following exposure to ultraviolet B irradiation
(Deliconstantinos et al, 1995). More recently, human keratinocytes
derived from an epidermal squamous cell carcinoma have been found
to contain a constitutive but not fully characterized NO synthase.
Preliminary evidence hints that augmentation of NO synthesis in these
cells after ultraviolet A irradiation may be directly related to the poor
prognosis of squamous cell carcinoma (Villiotou et al, 1995). Further
studies are clearly needed to address the question of whether the
inducible NO synthase pathway can also be elicited in ultraviolet-
irradiated cells with all the consequences that large amounts of NO
can exert on the various elements of the skin.
Ultraviolet B (UVB) irradiation also represents a major stimulus for
human skin pigmentation. Current evidence indicates that NO and
cGMP production in keratinocytes and melanocytes are required for
UVB-induced melanogenesis (Romero-Graillet et al, 1997). These
observations indirectly point to an involvement of NO in autocrine
and paracrine regulation of UVB-induced melanogenesis.
Moreover, it has been discovered that NO is produced in Langerhans
cells of human skin (Qureshi et al, 1996). From these studies it has
been concluded that NO may affect Langerhans cell functions such as
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microbicidal activity, antigen presentation, and cytotoxicity, and may
also affect adjacent keratinocytes and melanocytes.
Recently, it has become apparent that NO is also produced by other
cell types residing in the skin. Thus, expression of both the constitutive
and the inducible pathway has been demonstrated in dermal fibroblasts
and endothelial cells1 (Bull et al, 1996; Wang et al, 1996). It will be
of interest therefore to further elucidate the physiologic and/or
pathophysiologic roles of NO production in these cells with particular
reference to cutaneous inflammatory and immune responses.
Dermal papilla cells play an important role in hair growth and have
been shown to produce NO after exposure to bacterial endotoxin
(Nameda et al, 1996). Modulation of Ca21-activated K1 channels by
NO has been identified in these cells, although the biologic function
of this particular activity in human skin is not yet known.
Current evidence also indicates the existence of an enzyme-inde-
pendent mechanism of NO formation on the skin surface. This NO
formation is due to the acidification and reduction of the large pool
of nitrate within the sweat and is not blocked by inhibitors of NO
synthase (Weller et al, 1996). Because several pathogens, such as
Escherichia coli, Candida albicans, and Mycobacteria, have been shown to
be sensitive to NO, the chemical generation of NO on the skin surface
may provide a protective mechanism to regulate the growth of skin
commensal organisms and prevent infections with skin pathogens. This
is in accord with other studies that demonstrate anti-microbial actions
of acidified nitrite in the oral and gastrointestinal tract (Duncan
et al, 1995).
Taken together, data from the above studies strongly suggest that
most—if not all—NO responses known from other biologic systems,
such as vasodilation, neurotransmission, as well as cytotoxicity and
immunoregulation, are also of significant importance in human skin.
NO AND SKIN BIOLOGY: FUTURE PROSPECTS
Analysis of the widespread synthesis and biologic activity of NO
throughout the skin has shed some light on the mechanisms of action
of NO in cutaneous biology. Nevertheless, several important issues
need to be resolved. The most important of these questions concern
the regulation of cell growth and cell death, of cell–cell and cell–
matrix interactions, and of inflammatory and immune responses by
this pleiotropic mediator.
Cell growth and cell death In multicellular organisms tissue
homeostasis is maintained through a delicate balance between cell
proliferation and cell death. Arrest of cell division is a prerequisite for
cells to enter a program of terminal differentiation. Mitogenesis and
cytostasis can be induced by diverse intrinsic and extrinsic stimuli, and
convincing evidence suggests that alterations in this process contribute
to the pathogenesis of several human skin diseases, including psoriasis
and other hyperproliferative diseases (Bruch-Gerharz et al, 1996).
Several reports have focused on the potential of NO to influence the
proliferation and differentiation cascade in a number of mammalian
cells. From these elegant in vitro experiments it became evident that
the induction of iNOS can represent an important step to arrest cell
proliferation and to initiate the switch to terminal differentiation in
neuronal cells (Peunova and Enikolopov, 1995). Exogenously applied
NO alters gene expression and leads to monocytic differentiation in a
human leukemia cell line (Magrinat et al, 1992). Our findings of iNOS
being invariably expressed in keratinocytes from psoriatic skin lesions
strongly suggest an influence of NO on keratinocyte proliferation and
differentiation. Thus, NO could mediate cessation of growth and
synchronize commitment for differentiation in epidermal keratinocytes
(Fig 3). NO-induced cytostasis might be a mechanism to counteract
excessive mitogenesis in psoriatic skin lesions, as was previously
suggested for regenerative processes in other tissues known to express
iNOS, such as regenerating liver cells and endothelia (Peunova and
Enikolopov, 1995). Alternatively, iNOS expression in psoriatic skin
lesions could be inappropriate or too low to exert its differentiation-
promoting effects. Therefore, the role of NO in psoriasis and other
hyperproliferative diseases remains to be further characterized.
Cell–cell and cell–matrix interactions In human skin, normal
development as well as host responses to infection and tissue injury
Figure 3. Potential functions of NO in human skin. Schematic model of
a ‘‘generic’’ cell of the skin showing the potential targets and biologic
functions of NO in human skin.
are orchestrated through an intricate and ordered series of interactions
between cells resident to the skin as well as cytokines, growth
factors, and extracellular matrix proteins (Nathan and Sporn, 1991).
Pertubations in these cell–cell and cell–matrix interactions have been
shown to result in a loss of skin integrity, as characterized, for example,
during wound healing processes. Accumulating evidence exists that
NO synthesis in human fibroblasts might attenuate the pathophysiologic
sequelae in wound healing early during the inflammatory stages and
later during stages of proliferation and tissue remodeling (Wang et al,
1996). More recently, reduced NO synthesis has been demonstrated
in fibroblasts of hypertrophic scar tissue (Wang et al, 1997). These
findings suggest that changes in NO levels can lead to significant
alterations of cellular responses to wounding (Fig 3). Several cytokines
and growth factors that are known regulators of iNOS expression
control critical aspects of wound healing, suggesting a complex network
of autocrine and paracrine cellular responses.
Regulation of inflammatory and immune responses NO, in
addition to being directly cytotoxic for normal cells and certain tumor
cells, is known to play an important role in the regulation of innate
immune and inflammatory responses (Xie and Nathan, 1994; Kro¨ncke
et al, 1997). The well-documented expression of inducible NO synthesis
in keratinocytes and Langerhans cells of the skin may influence several
immunologic reactions in the skin. NO downregulates Th1-like
responses as evidenced for example by observations in iNOS deficient
mice that develop a significantly stronger Th1 type of immune response
than their wild-type or heterozygous littermates (Wei et al, 1995). Th1
cells, characterized by secretion of IFN-γ, provide major support for
the development of cellular immune reactions.
Consistent with a key role of iNOS in the regulation of inflammatory
and immune responses in human skin is the finding of iNOS expression
in dermal microvascular endothelial cells.1 In inflammatory processes,
the regulation of leukocyte trafficking involves a complex interplay
between adhesion molecules as well as chemokines and cytokines
produced by both leukocytes and endothelial cells (Nathan and Sporn,
1991; Suschek et al, 1993). Convincing evidence indicates that iNOS
expression in endothelial cells mediates via autocrine or paracrine
pathways the production of various mediators that resolve or progress
to an inflammatory state (Fig 3).
Finally, several lines of evidence indicate the existence of the
inducible NO pathway in human monocytes, and CD23 has been
reported to play a pivotal regulatory role in this process (Dugas et al,
1995). These observations suggest that the CD23/NO transduction
cascade could be enhanced to provide a potent nonspecific defense
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mechanism and could also have functional implications in the develop-
ment of IgE-dependent processes by regulating IgE production by
human B cells. Another important aspect of the role of NO in the
regulation of immune functions is the recent observation that γδ T
cell-induced NO production enhances resistance to mucosal candidiasis
possibly by upregulating macrophage NO production and candidacidal
activity (Jones-Carson et al, 1995).
Moreover, novel and unexpected twists to the NO story are being
uncovered with increasing frequency (Adler et al, 1997; Kro¨ncke et al,
1997) and will provide additional clues to a detailed molecular
understanding of the role of NO in skin biology.
NEW DRUG HOPES
Recognition of the role of NO in a wide spectrum of human diseases
has resulted in attempts to modulate NO production for therapeutic
purposes. Several pharmacologic agents have been described that can
release NO or inhibit NO production (Kerwin and Heller, 1994).
NO donors include the organic nitrates such as nitroglycerin or
sodium nitroprusside, S-nitrosothiols, as well as diazeniumdiolates
(NONOates) that generate NO or related redox species in a controlled
manner (Kro¨ncke et al, 1995). Interestingly, NO-releasing drugs such
as sodium nitroprusside and nitroglycerin have been used for more
than a century to promote coronary vasodilation, but the mechanism
of this vasodilation has only recently been fully understood. In this
context, an attractive possibility for the beneficial use of NO donors
in human skin would be the attempt to ameliorate Raynaud disease
by counteracting the vasoconstrictive process (Ånggård, 1994).
Inhibition of NO generation has also found applications in clinical
medicine. Thus, inhibitors of iNOS have successfully been used for
the treatment of migraine attacks and also of acute or chronic
inflammatory conditions, such as chronic ileitis, osteoarthritis, and
immune complex-mediated vascular injury in lung and dermal tissue
(Mulligan et al, 1991; Ånggård, 1994; Lassen et al, 1997). Inhibitors of
NO production may also provide a valuable mode of therapy to relieve
symptoms of flushing and erythema in the skin3–5 (Goldsmith et al,
1996); however, most NO synthase inhibitors developed so far inhibit
both the constitutive and the inducible isoforms of NO synthase, albeit
at different concentrations. Therefore, the widespread use of NO
synthase inhibitors is currently limited, because NO is essentially
involved in many different physiologic functions (Kro¨ncke et al, 1995).
The development of selective inhibitors of NO production will be the
first step towards improving efficacy and reducing toxicity of treatment
with NO synthase antagonists.
CONCLUDING REMARKS
There is now little doubt that NO is a novel and powerful signaling
molecule that provokes many types of cellular responses and affects
the functions of most organ systems. The tremendous impact NO has
had on research in biology and medicine was reflected by the
nomination of NO as the ‘‘molecule of the year 1992,’’ an annual
distinction conferred by the journal Science (Koshland, 1992). Whereas
the role of NO in many biologic systems is now well documented,
we are still just beginning to understand how NO acts within the
molecular cascade of cell growth and cell death, inflammation, and
immune response in human skin. It is already apparent that this
molecule is involved in normal physiologic processes of the skin by
exerting regulatory functions in vascular homeostasis, melanogenesis,
and reponses to ultraviolet irradiation. Increasing evidence also exists
for a critical role of NO in pathologic processes of the skin. These
include psoriasis and other immune-mediated skin diseases as well as
skin cancer. Characterization of the role of NO in cutaneous disease
3Hayes NA, Foreman JC, Dowd PM: Nitric oxide synthase in dithranol-
induced erythema. J Invest Dermatol 103:435, 1994 (abstr.).
4Leslie TA, Levell NJ, Bewley AP, Hayes NA, Foreman JC, Woolf CJ,
Dowd PM: The role of nitric oxide and cutaneous nerves in the erythema of
psoriasis and atopic eczema. J Invest Dermatol 103:435, 1994 (abstr.).
5Sauermann G, Jaspers S, Hoppe U, Salzer B, Steinkraus V: Influence of NO-
synthase antagonists in rosacea patients. J Invest Dermatol 108:657, 1997 (abstr.).
will not only provide an important addition to our understanding of
cutaneous biology but also is likely to be the foundation for the
development of new therapeutic approaches that can modify, arrest,
or reverse the course of human skin disease.
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